Single Dose Oral Bioequivalence Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets

Single dose oral bioequivalence study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg and 'Trintellix' (Vortioxetine) Tablets 20 mg in healthy adult human subjects under fasting conditions. * To compare and evaluate the oral bioavailability of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg (administered without water and with water) with that of 'Trintellix' (Vortioxetine) Tablets 20 mg in healthy, adult, human subjects under fasting conditions. * To monitor the safety and tolerability of the subjects. An open label, randomized, three-period, three-treatment \[Treatment A (test product administered without water), Treatment B (test product administered with water) and Treatment C (Reference product administered with water)\], six-sequence, crossover, balanced, single dose oral bioequivalence study.